secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-06-15T13:18:44+00:00
Accession:  0001628280-26-043042
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics reports 29% ORR for CTIM-76 in Phase 1 PROC trial; FDA Fast Track granted
--------------------------------------------------------------------------------

- 29% confirmed overall response rate per RECIST v1.1 in heavily pretreated PROC patients (median 7 prior lines).
- Cytokine Release Syndrome limited to Grade 1 in 11% of PROC patients at active doses; supports outpatient dosing.
- PK data supports exploration of Q3W dosing in 2H 2026; Phase 1b dose expansion planned for 2027.
- CTIM-76 granted FDA Fast Track Designation for platinum-resistant ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/0001628280-26-043042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026043042/cntx-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer